The incidence of thyroid cancer is increasing year by year, with more and more patients. The question that many patients are very concerned about is whether the disease affects lifespan? Let’s combine the US SEER database to learn about whether thyroid cancer affects life span?
Let’s first look at the incidence and mortality of thyroid cancer in the US SEER database:
The above chart shows the number of new cases and deaths per 100,000 people in the United States each year: the estimated number of new cases of thyroid cancer in the United States in 2019 is 15.8 per 100,000 people per year, while the annual death toll is 0.5 per 100,000 people. In other words, the number of deaths accounts for only 3% of the number of patients, and it is roughly estimated that 97% of people will not die of aramid cancer. (But here does not mean that the cure rate is 97%. Some thyroid cancers can survive with tumors after standardized treatment, and ultimately die of atherosclerosis.)
Among these 3% of dead patients, what is the age of death? Look at the table below:
From the table above, it can be seen that most patients who die of aratopic cancer are above 55, and the median age is 73 years old. Most patients with aratopic cancer can live until they are 73 years old. (Many patients start to feel that they can only live to 73 years old when they see this. This is not the case. Only the age of 3% of patients who died of thyroid cancer, and 97% of patients with thyroid cancer did not die of thyroid cancer in the end, which is not included.)
In summary, the incidence of thyroid cancer has increased year by year, but the mortality rate has been stable and at a very low level. About 97% of patients with thyroid cancer will not eventually die of the disease, that is, they will die naturally and will not affect their lifespan. Only 3% of patients with A-Cancer life span are affected, and these 3% can live to 73 years of age on average.
At present, the treatment level of tertiary hospitals in my country's major cities has been in line with the international level, but the overall 5-year survival rate of patients with A-carcinoma in the country is still a certain gap with developed countries in Europe and the United States. The main reason is that the health awareness in relatively backward areas is poor, the disease is discovered late, and there are many locally advanced cases. We need to carry out screening of A-carcinoma in backward areas, early detection and early treatment to improve the overall survival rate of A-carcinoma in my country.
Note: Data and charts are excerpted from the US SEER database
(Medical cards have been added here, please go to the Toutiao client to view)
#Liu Anyang Doctor Online Studio# #thyroid##Health Truth Pavilion##Qingfeng Plan#
